Skip to main content
. Author manuscript; available in PMC: 2025 Nov 1.
Published in final edited form as: Ann Neurol. 2024 Aug 3;96(5):944–957. doi: 10.1002/ana.27049

Table 3.

Individual-level performance summary for subgroup analyses.

MRI-positive Subgroup
Sensitivity Specificity Accuracy AUC
PTs vs. HCs 0.9 ± 0.041 0.937 ± 0.071 0.924 ± 0.044 0.952 ± 0.018
PTs vs. DCs 0.875 ± 0.068 0.915 ± 0.054 0.9 ± 0.03 0.938 ± 0.029
Type II vs. Non-type-II 0.983 ± 0.033 1.0 ± 0.0 0.988 ± 0.025 0.99 ± 0.021
Type IIa vs. IIb 0.712 ± 0.168 0.75 ± 0.194 0.725 ± 0.149 0.714 ± 0.148
MRI-negative Subgroup
PTs vs. HCs 0.919 ± 0.049 0.937 ± 0.053 0.93 ± 0.027 0.956 ± 0.019
PTs vs. DCs 0.9 ± 0.053 0.938 ± 0.058 0.923 ± 0.026 0.951 ± 0.012
Type II vs. Non-type-II 0.838 ± 0.098 0.7 ± 0.141 0.765 ± 0.059 0.731 ± 0.07
Type IIa vs. IIb 0.575 ± 0.225 0.675 ± 0.16 0.625 ± 0.125 0.6 ± 0.166

AUC = area under curve; DCs = disease controls; HCs = healthy controls; MRF = magnetic resonance fingerprinting; MRI = magnetic resonance imaging; PTs = patients.